COVID vaccines can't keep up with new Omicron subvariants
Just when you thought it was safe to go back in the air.
New subvariants of the Omicron strain of the COVID-19 virus "appear to be even more immune-resistant than the original," Axios reported Wednesday.
The original Omicron strain was known as BA.1, but that's old hat by now. All the cool kids are getting BA.4, or even BA.5. Unfortunately, while the virus has moved on, vaccine makers are stuck in the past.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Per Axios, "[c]linical trials are underway to study tweaked versions of the Pfizer and Moderna vaccines" designed to tackle O.G. Omicron, but by the time they're ready — this fall at the earliest — it might be too late.
"[I]t's really unclear that it's going to be much of an improvement versus the original vaccine when BA.4 and BA.5 are so significantly different than the original Omicron," said infectious disease specialist Celine Grounder.
Axios also notes that although the new Omicron subvariants are more likely to cause breakthrough infections — even among those who've already had BA.1 — that's no reason to skip the jab. Three doses of the existing vaccine still provide effective protection against hospitalization and death.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Grayson Quay was the weekend editor at TheWeek.com. His writing has also been published in National Review, the Pittsburgh Post-Gazette, Modern Age, The American Conservative, The Spectator World, and other outlets. Grayson earned his M.A. from Georgetown University in 2019.
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published